Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.
Partnerships Xiamen Amoytop Biotech Co., Ltd: exclusive Greater China license, $25.0M upfront (net of tax, received Jul 2026), up to $420M in clinical/regulatory/sales milestones, tiered high single-digit royalties
Indications
Chronic HBV infection(Phase 2)
Catalysts
— late Q3 2027
Status note Phase 2 B-SUPREME study (NCT06963710, ~250 subjects, 48-week monotherapy vs tenofovir disoproxil fumarate) enrollment completed (131 HBeAg+ Part 1a, 114 HBeAg- Part 2a). Received FDA Fast Track Designation and China NMPA/CDE Breakthrough Therapy Designation for chronic HBV infection.
Target HBV RNA transcripts (HBsAg mRNA); also TLR8 agonist activity
Partnerships Xiamen Amoytop Biotech Co., Ltd: research collaboration; Amoytop holds Greater China rights and funds China development; earned $3.0M milestone at IND-enabling start (Jan 2026) and $3.0M at China IND approval (Jul 2026); eligible for up to $109.0M in development/commercialization milestones plus tiered royalties
Indications
Chronic HBV infection(Preclinical)
Catalysts
— Q3 2026
Status note Next-generation ASO discovered under Amoytop collaboration. Amoytop received IND approval in China in July 2026; Phase 1 in healthy volunteers with planned HBV-infected cohort (following 150 mg MAD cohort, Q4 2026) to be sponsored and performed by Amoytop. Each party funds its own development; Aligos may run a Phase 2 in 2028.
Status note Phase 2a HERALD study (2024) completed. Obesity work is preclinical (diet-induced obese mouse data for combination with incretin receptor agonists). Company is evaluating options to fund continued development, including potential out-licensing; not explicitly discontinued.
Per-asset detail extracted from the 10-Q filed 2026-08-06. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
Sponsor-matched active trials from ClinicalTrials.gov (2 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.
Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.
Get the weekly biotech catalyst rundown. Cash runways, financings, and trial readouts for all 714 stocks.